Mammostrat is an immunohistochemistry breast cancer prognostic test that classifies an individual as having a high-, moderate-, or low-risk of breast cancer recurrence. The Mammostrat test is currently on the market and recommended for postmenopausal, node-negative estrogen receptor expressing breast cancer patients.

Pulmotype is a five antibody immunohistochemistry aid for the classification of non-small cell lung cancer into adenocarcinoma versus squamous cell carcinoma subtypes.

Pulmostrat is a seven antibody prognostic immunohistochemistry test in development for early stage lung cancer. Pulmostrat categorizes an individual's risk of lung cancer recurrence following surgery and should prove useful for helping with adjuvant therapy decisions.